

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/051,681	01/16/2002	Daniel Cohen	G-101.US05REG	1458
23557	7590 03/12/2004		EXAM	INER
	CHIK LLOYD & SALIWA	HORLICK, K	HORLICK, KENNETH R	
A PROFESSIONAL ASSOCIATION 2421 N.W. 41ST STREET			ART UNIT	PAPER NUMBER
SUITE A-1			1637	
GAINESVILLE, FL 326066669			DATE MAILED: 03/12/2004	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
<b>\</b>	10/051,681	COHEN ET AL.
Office Action Summary	Examiner	Art Unit
	Kenneth R Horlick	1637
The MAILING DATE of this communication		th the correspondence address
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REI THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a  - If NO period for reply is specified above, the maximum statutory per  - Failure to reply within the set or extended period for reply will, by sta Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b).	N. R. 1.136(a). In no event, however, may a recept within the statutory minimum of thirtidod will apply and will expire SIX (6) MON atute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. IANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on	· •	
2a) This action is <b>FINAL</b> . 2b) T	his action is non-final.	
3) Since this application is in condition for allow	wance except for formal matte	ers, prosecution as to the merits is
closed in accordance with the practice unde	er Ex parte Quayle, 1935 C.D	. 11, 453 O.G. 213.
Disposition of Claims		
4) Claim(s) 1-18 is/are pending in the applicati	ion.	
4a) Of the above claim(s) is/are without	drawn from consideration.	
5) Claim(s) is/are allowed.		
6)☐ Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) <u>1-18</u> are subject to restriction and/	or election requirement.	
Application Papers		
9) The specification is objected to by the Exam	iner.	
10) The drawing(s) filed on is/are: a) a	accepted or b)  objected to I	by the Examiner.
Applicant may not request that any objection to t	the drawing(s) be held in abeyan	ice. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the con	rection is required if the drawing(	(s) is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the	Examiner. Note the attached	d Office Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for fore	ign priority under 35 U.S.C. §	119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
<ol> <li>Certified copies of the priority docume</li> </ol>	ents have been received.	
<ol><li>Certified copies of the priority docume</li></ol>	ents have been received in A	pplication No
<ol><li>Copies of the certified copies of the p</li></ol>	riority documents have been	received in this National Stage
application from the International Bur	• • • • • • • • • • • • • • • • • • • •	
* See the attached detailed Office action for a l	list of the certified copies not	received.
\		
Attachment(s)		
1) Notice of References Cited (PTO-892)	4) Intensious 9	Summary (PTO-413)
2) Notice of Practices Cited (P10-982)  Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s	s)/Mail Date
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/		nformal Patent Application (PTO-152)
Paper No(s)/Mail Date	6) [] Other:	•

Application/Control Number: 10/051,681

Art Unit: 1637

1. On 02/27/04, applicant faxed directly to the examiner a copy of a preliminary amendment filed 05/24/04 which added new claims 14-18. This amendment has been taken under consideration. However, as said amendment was not scanned into the official electronic file previously, applicant is requested to send another copy of it along with the response to this paper, so it can be scanned into the official record (official faxes may no longer be received directly by examiners at their RightFAX numbers).

## 2. Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9 and 12-18, drawn to methods of assessing a candidate molecule for the treatment of a CNS disorder based upon inhibition of DAO or DDO, and to methods of using such a molecule in the treatment of schizophrenia or bipolar disorder, classified in class 544, subclass 1.
- II. Claim 10, drawn to a method of diagnosing schizophrenia, depression or bipolar disorder based on nucleic acid detection, classified in class 435, subclass 6.
- III. Claim 11 (partial), drawn to a nucleic acid molecule comprising SEQ IDNO:1-6, classified in class 536, subclass 23.2.
- IV. Claim 11 (partial), drawn to a polypeptide comprising SEQ ID NO:8-10, classified in class 530, subclass 350.

Application/Control Number: 10/051,681 Page 3

Art Unit: 1637

The inventions are distinct, each from the other because of the following reasons:

A) Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to different methods with completely different steps and parameters.

- B) Inventions (I,II) and (III,IV) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to methods and products which have no relation or use with said methods.
- C) Inventions III and IV are independent because III is drawn to nucleic acid and IV to polypeptides. Polypeptides and nucleic acids have distinct chemical structures and physical properties, the former composed of amino acids and the latter composed of nucleotides. Further, they have distinct utilities, such as use of nucleic acids in hybridization and use of proteins for enzymatic function. Therefore, the above inventions are novel and unobvious over each other.

Application/Control Number: 10/051,681

Art Unit: 1637

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

- 3. A telephone call was made to Frank Eisenschenk on 02/19/04 to request an oral election to the above restriction requirement, but did not result in an election being made.
- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/051,681

Art Unit: 1637

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kenneth R Horlick whose telephone number is 571-272-0784. The examiner can normally be reached on Monday-Thursday 6:30AM-5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kenneth R Horlick Primary Examiner

Art Unit 1637

03/04/04